{"name":"Nielsen BioSciences, Inc.","slug":"nielsen-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Candida albicans Skin Test Antigen","genericName":"Candida albicans Skin Test Antigen","slug":"candida-albicans-skin-test-antigen","indication":"Other","status":"marketed"},{"name":"Spherule-derived coccidioidin","genericName":"Spherule-derived coccidioidin","slug":"spherule-derived-coccidioidin","indication":"Coccidioidomycosis prevention in individuals at high risk","status":"phase_3"},{"name":"Candin, Intradermal Solution","genericName":"Candin, Intradermal Solution","slug":"candin-intradermal-solution","indication":"Candida-related conditions (specific indication in Phase 3 development unclear)","status":"phase_3"}]}],"pipeline":[{"name":"Candida albicans Skin Test Antigen","genericName":"Candida albicans Skin Test Antigen","slug":"candida-albicans-skin-test-antigen","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Spherule-derived coccidioidin","genericName":"Spherule-derived coccidioidin","slug":"spherule-derived-coccidioidin","phase":"phase_3","mechanism":"Spherule-derived coccidioidin is a vaccine derived from the spherules of the Coccidioides fungus, which stimulates an immune response against the fungus.","indications":["Coccidioidomycosis prevention in individuals at high risk"],"catalyst":""},{"name":"Candin, Intradermal Solution","genericName":"Candin, Intradermal Solution","slug":"candin-intradermal-solution","phase":"phase_3","mechanism":"Candin is a candida albicans antigen preparation that stimulates delayed-type hypersensitivity and cell-mediated immune responses against candida infections.","indications":["Candida-related conditions (specific indication in Phase 3 development unclear)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxNeUpIQXNZVy04VUptaGd1dDRMa1YwWjRHQTdsUXg2R1RuV0xlX2g5M1diZFpXNmszX1pIMjJ6SERvcmpaN1RlRmtBSWtITVVMVERMcU55UHVsZzUxTDRoVVhsZ3lpQmJVM2psYzRWZ0ZzbTF1YzJKcUM2WDRXNlJtQTZOb1NXSDJkUW9kZl9iUXE0SDNMX2htMklDd2dGNmlCbkN1c2ZpOVp2VlNzZzItS1ZBSUstclUyQ1IxcHVKYTkwUDQxRl94eVRLZnlRVEN2RGtBbnkyalNINEJucV96Vy1XTXpDWk9IdGdPdWVOVkZadGVvY21hYlRGLTdJSklnNGpuSmNKX0ZwcTJuSmJtbmJhQUtrTmthQkVINmtoWFVUWEU1ZmJZU1IwTklKX3N4Tm5rVGtuN1NMQWFqbFQ1YXh2dVZmWENTemthWm1IZw?oc=5","date":"2026-04-07","type":"regulatory","source":"Barchart.com","summary":"Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight -","headline":"Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeut","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNTlNUMDVON0lvSzhreTBCd04xVzFyRk5rZ2VKYUxxWTA1YWpkQU8yS1FNakotc3B5MkkybUdhc2s2XzNtR2FFWndOaHZFb0NMbzNRbUoteVEyV0hUTjdwZ3BmN3dwUzAxVUdWck5JOWNCMWdBWEs3RUNFUjlwVkVGenZ0Sk5SanR6SkRLaDZhdU9zNEtHR3c?oc=5","date":"2026-04-06","type":"earnings","source":"openPR.com","summary":"Common Warts Market: Expanding Revenue Landscape to 2034 - DelveInsight - openPR.com","headline":"Common Warts Market: Expanding Revenue Landscape to 2034 - DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOYnVQMmNVdlNJRlZkd0JabkRNRnA1akNUTkJQN0tDUzRwaXFMMTg0T2ZQdGhOSTEzelE5Z3JtNTdXRzBKYWdLQWNCTWlyckt4VEVQQmo0LUNtWlpQcm9YcXUxYXFodjF4Y0FNYThSRE9BOHZha2JUaHFvNGVoSlpHT3VBWkY5WTY1dXQ1UEstdVFFUGd0S2NmZnh3Qm9Ua3RUNkN3?oc=5","date":"2026-04-06","type":"pipeline","source":"openPR.com","summary":"Warts Therapeutics Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsight - openPR.com","headline":"Warts Therapeutics Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOakowRFJEQTlLd3lOYnlpdnFUSHdfNmN5NWpRb1VxcE1IZnlNV0tvSzR6Zjg4b1dOWWI3QlRCanhrRzV3dTR3VTRROGx0ZHd1YUZDSzdmb0d1X1htRVFYdkFTcVNPSGhjdmp3NkVWclRycGV3RGZRSW81eEZjaGhBYTFEc2JrdFZqTzY0YVk2WklONWlLa0xxUnloTl9jQzRIV1puYUJKMG5BVzFIajlETDl2Q3Q2aHVyaTVsUW00a3o4c1ROVXVfWThva08wMnBzR2puZ2NsRHg?oc=5","date":"2025-10-23","type":"deal","source":"Business Wire","summary":"Nielsen BioSciences Announces Expanded CANDIN License Agreement with Maruho Co. Ltd. - Business Wire","headline":"Nielsen BioSciences Announces Expanded CANDIN License Agreement with Maruho Co. Ltd.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPRk1IRXFYbWNPZjN0MVlYMFl2WDhGUEd4Q05yZTVCOW81MUMybkx3VERSUXlrX1Z5dzB5TDY3RlFHSFBmWVlLR0ktZ2wzWVFqYjJBeFBLRHBRbzgyaHg1NjI0bXRkUjJIOFVrYjlHRmw0d1BOU3RXRHJsanhCZG5WZ21Fcw?oc=5","date":"2024-11-20","type":"pipeline","source":"BioPharma Dive","summary":"What might a Trump administration mean for the Biosecure Act? - BioPharma Dive","headline":"What might a Trump administration mean for the Biosecure Act?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOamVWYmxyVUs0cVQtUlNzXzRUeG5JWEFiOUNfaVZ2dEpYOGFRRjdwTUpmWWZnQTJjNXdvMmdfWV81Tm1pbVZuT01fQ0VMVGRiMnZab192WTZOMWtnc2NZRDZQSDhwaS1LRTM2Z05RR0JNdnc2OWRKckU2YzJiMjJQZ2FoN1U3ckYtSnFRdHU5T2dWOGFL?oc=5","date":"2024-09-16","type":"pipeline","source":"BioPharma Dive","summary":"As Biosecure bill advances, drugmakers prepare for prospect of China pivot - BioPharma Dive","headline":"As Biosecure bill advances, drugmakers prepare for prospect of China pivot","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNTE53ZGpHNTFKSWgwb2dRVHczZjFTWXc2alJreVdqSC13YWpuMjV0bmRqNHRLNFhUdUNYakRiemtMTkI1S0RQMTM0TDZRR2RVNk1zVDNjbFY1X3JjLVVhc3AzRzZzdXpoWVppbFY0MmFhMUp3SHlSdTl5Z3lXN1BMVWF3dG9NTk5XcDVhZDNwdlFSTTByY013ZHVOa1NRTFFuamI3bUxLb01hOVdp?oc=5","date":"2023-12-05","type":"pipeline","source":"BioMelbourne Network","summary":"BioCurate Board Announces Kathy Nielsen PhD M.Pharm M. IP. Law RTTP GAICD as New CEO - BioMelbourne Network","headline":"BioCurate Board Announces Kathy Nielsen PhD M.Pharm M. IP. Law RTTP GAICD as New CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTFA0T0pQZUU4OVpKSU9NV3dWTUdnem9XRGNvY3ZOX0NHVTdMQ2ZaSWdCOFZCUThJLXZRY2VielVLdzktTVR1b0laWTl3dEpaZGI2TDlEOUg2QnY?oc=5","date":"2023-11-16","type":"pipeline","source":"Nielsen","summary":"Karthik Rao - Nielsen","headline":"Karthik Rao","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOc3I0eHNjQ2pTM3pQQkFLcHMzck5FNkhjQ3RVVnQ0SkxUSGdSb3ViTzVaNmJRbERnU3lQSlFJc2RWRGx4V01USmdQbi1mN0luRTEtdV9TckZwcTRhc0Rvb3lCSDVUTFVDT2taTktZdFJ0QkdNZDhRSXBOY2ZRTDlQT0xNVGxUN0xXZ0JpbmNCcw?oc=5","date":"2023-05-27","type":"deal","source":"San Diego Business Journal","summary":"Nielsen BioSciences Inks $100M Deal - San Diego Business Journal","headline":"Nielsen BioSciences Inks $100M Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQcTdlVk05eHVRV201Y1JVM3VwQzJrUVhrakFWeXFNSkl4aWhYZXM1RHdmQTl4LTNhaUFxeVB1cVM3ZkEtaVdPZ1lYSG5pU0J4NE1sN2hDVlViYjZrZmtocjBBeE90OWV2dlE1dHYtSTVzY0pOUXJVYVJubGh0S183VXp3alh2ckRzZ2ZQSFZsNTZTVFY5ZnVQclFLWV8tYUZlZ1dUemNsX2VXREQ3dE1wY3pmTm9CY2lBd0hNSFdLY0dUZUdyVUdWUmJqOGV4MHgwd3c?oc=5","date":"2023-05-25","type":"pipeline","source":"Healio","summary":"Nielsen enters agreement with Maruho for marketing rights to verruca vulgaris treatment - Healio","headline":"Nielsen enters agreement with Maruho for marketing rights to verruca vulgaris treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE41X25NeF92SW5YeFNHMEcxTHA2R1k5bVNJanJ2YTRlSzZ6UE9GdEc1ODVkWTYyNkRKMVB3ejZpdzY5WjFtSENtbnFYT3ZxMkswUHlQYzR4TUQtY2c2LXZtbk5wNEU3VVB5dDRjN3p3?oc=5","date":"2021-03-25","type":"pipeline","source":"BioSpace","summary":"BioSpace Movers & Shakers, March 26 - BioSpace","headline":"BioSpace Movers & Shakers, March 26","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}